Project Grant R21AG085456
Award Date
9/30/24
Completion Date
6/30/26
Dollars Obligated
$679K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Fort Collins, CO 80521, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant (CFDA 93.866 - Aging Research) to Florida International University to develop biotherapeutic nanogels for the treatment of Alzheimer's disease. The goal is to create a novel nanogel system that can effectively cross the blood-brain barrier, inhibit amyloid-beta aggregation, and reduce oxidative stress and neuroinflammation associated with Alzheimer's. The project will focus on improving the nanogel formulation for enhanced...
The National Institute on Aging (NIA) awarded a $1,512,892 Project Grant under the Aging Research program (CFDA 93.866) to 3P Biotechnologies, Inc. to develop a targeted nanoformulation delivery system for the bioactive curcuminoids, curcumin and bisdemethoxycurcumin, to treat Alzheimer's disease (AD). The Phase I project aims to optimize exosome-based formulations of these compounds and assess their biodistribution and toxicity in mice, as well as determine the efficacy of folic...
This Project Grant award from the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866) provides $3,038,050 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to study the molecular mechanisms of Alzheimer's disease. The funded research aims to discover a novel oxidative stress pathway that targets microglia, the immune cells in the brain, leading to their dysfunction and detrimental consequences in Alzheimer's disease. The goal is to develop...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $636,000 to the University of Pittsburgh to investigate the use of NOX2 small molecule inhibitors as a potential therapeutic strategy for treating Alzheimer's disease (AD). The researchers aim to evaluate the ability of two novel, orally bioavailable, and blood-brain barrier penetrant NOX2 inhibitors (CPP11G and CPP11H) to improve cerebrovascular blood flow, reduce amyloid-beta deposition, and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $654,238 to The University of Texas Health Science Center at San Antonio to study the role of senescent cells in Alzheimer's disease and related dementias (ADRD). The primary goals are to: Identify molecular markers and changes in the microenvironment of senescent neurons compared to healthy neurons, with a focus on their contribution to neuronal death in brain aging and ADRD (R21 phase). Use...
This $6,226,692 project grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will support research to examine the role of neuronal hyperexcitability and proteostasis (protein homeostasis) in the development of Alzheimer's disease (AD). The primary focus is on investigating how modifications in brain activity, particularly in the locus coeruleus (LC) and hippocampus (HPC) regions, can lead to the key pathological hallmarks of AD....
This Project Grant award of $437,875 from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund a 2-year research project at the University of California, San Diego to quantify neurovascular protein lifetimes in the central nervous system under healthy, aging, and Alzheimer's disease conditions. The key objectives are to generate a comprehensive atlas of neurovascular protein lifetimes and identify changes associated with aging and Alzheimer's disease. The project will...